{"title":"The effect of intravenous calcium gluconate on the prevention of ovarian hyperstimulation syndrome. (A randomized clinical trial)","authors":"Marzieh Lotfalizadeh , Nayereh Khadem , Tahere Sadeghi , Nafiseh Jahanpak , Mahbobeh Mahmoudinia , Pardis Faraji , Faezeh Zakerinasab , Malihe Mahmoudinia","doi":"10.1016/j.jogoh.2024.102850","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Oral Cabergoline and intravenous Calcium have the potential to prevent Ovarian Hyperstimulation Syndrome (OHSS) in assisted reproductive technology by regulating the activity of the Vascular Endothelial Growth Factor (VEGF) receptor. The purpose of this study was to examine the effect of Cabergoline with intravenous Calcium versus oral Cabergoline alone on the overall rate of OHSS.</div></div><div><h3>Methods</h3><div>This study is a randomized clinical trial which was carried out in Milad Infertility Center affiliated with Mashhad University of Medical Sciences, Mashhad, Iran between April 2016 and January 2018. A total of 192 patients were randomly assigned into two groups. The control group received oral Cabergoline and the intervention group received Calcium gluconate in addition to Cabergoline. A total rate of OHSS, moderate and severe OHSS were measured in both groups.</div></div><div><h3>Results</h3><div>The demographic characteristics of the participants and the types of drugs used showed homogeneity between the intervention and control groups (<em>P</em> > 0.05). Furthermore, there was no significant difference between the two groups in terms of the number of the follicle, oocytes obtained, metaphase II oocytes, the number of embryos, and the rate of fertilization. Regarding the incidence of OHSS, 26.2 % of participants in the control group experienced OHSS, while the occurrence rate was 15.7 % in the intervention group (<em>P</em> = 0.401). The incidence of severe OHSS in the control group and intervention group was 7.1 % and 3.6 %, respectively.</div></div><div><h3>Conclusion</h3><div>Intravenous injection of Calcium gluconate can be effective in preventing Ovarian Hyperstimulation Syndrome.</div></div>","PeriodicalId":15871,"journal":{"name":"Journal of gynecology obstetrics and human reproduction","volume":"53 10","pages":"Article 102850"},"PeriodicalIF":1.7000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of gynecology obstetrics and human reproduction","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468784724001296","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
Oral Cabergoline and intravenous Calcium have the potential to prevent Ovarian Hyperstimulation Syndrome (OHSS) in assisted reproductive technology by regulating the activity of the Vascular Endothelial Growth Factor (VEGF) receptor. The purpose of this study was to examine the effect of Cabergoline with intravenous Calcium versus oral Cabergoline alone on the overall rate of OHSS.
Methods
This study is a randomized clinical trial which was carried out in Milad Infertility Center affiliated with Mashhad University of Medical Sciences, Mashhad, Iran between April 2016 and January 2018. A total of 192 patients were randomly assigned into two groups. The control group received oral Cabergoline and the intervention group received Calcium gluconate in addition to Cabergoline. A total rate of OHSS, moderate and severe OHSS were measured in both groups.
Results
The demographic characteristics of the participants and the types of drugs used showed homogeneity between the intervention and control groups (P > 0.05). Furthermore, there was no significant difference between the two groups in terms of the number of the follicle, oocytes obtained, metaphase II oocytes, the number of embryos, and the rate of fertilization. Regarding the incidence of OHSS, 26.2 % of participants in the control group experienced OHSS, while the occurrence rate was 15.7 % in the intervention group (P = 0.401). The incidence of severe OHSS in the control group and intervention group was 7.1 % and 3.6 %, respectively.
Conclusion
Intravenous injection of Calcium gluconate can be effective in preventing Ovarian Hyperstimulation Syndrome.
目的通过调节血管内皮生长因子（VEGF）受体的活性，口服卡麦角林和静脉注射钙剂可预防辅助生殖技术中的卵巢过度刺激综合征（OHSS）。本研究的目的是考察卡贝戈林联合静脉注射钙剂与单独口服卡贝戈林对OHSS总发生率的影响。方法本研究是一项随机临床试验，于2016年4月至2018年1月期间在伊朗马什哈德市马什哈德医科大学附属米拉德不孕不育中心进行。共有 192 名患者被随机分配到两组。对照组口服卡贝戈林，干预组在服用卡贝戈林的同时服用葡萄糖酸钙。结果干预组和对照组参与者的人口统计学特征和使用的药物类型显示具有同质性（P>.05）。此外，两组在卵泡数量、获得的卵母细胞数、分裂期 II 卵母细胞数、胚胎数和受精率方面均无明显差异。关于OHSS的发生率，对照组有26.2%的参与者发生过OHSS，而干预组的发生率为15.7%（P=0.401）。结论静脉注射葡萄糖酸钙可有效预防卵巢过度刺激综合征。
期刊介绍：
Formerly known as Journal de Gynécologie Obstétrique et Biologie de la Reproduction, Journal of Gynecology Obstetrics and Human Reproduction is the official Academic publication of the French College of Obstetricians and Gynecologists (Collège National des Gynécologues et Obstétriciens Français / CNGOF).
J Gynecol Obstet Hum Reprod publishes monthly, in English, research papers and techniques in the fields of Gynecology, Obstetrics, Neonatology and Human Reproduction: (guest) editorials, original articles, reviews, updates, technical notes, case reports, letters to the editor and guidelines.
Original works include clinical or laboratory investigations and clinical or equipment reports. Reviews include narrative reviews, systematic reviews and meta-analyses.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
